Skip to main content
S.C.P.C logo

S.C.P.C — Investor Relations & Filings

Ticker · 1720 ISIN · TW0001720001 TW Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2024-05-07 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1720

About S.C.P.C

http://www.standard.com.tw

Standard Chemical & Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical manufacturer established in 1967. The company specializes in the research, development, production, and marketing of a wide range of pharmaceutical products, including generic Western medicines, Active Pharmaceutical Ingredients (APIs), and healthcare supplements. Its therapeutic portfolio covers diverse areas such as cardiovascular, metabolic, respiratory, anti-infective, and musculoskeletal systems, as well as dermatological and urogenital treatments. As a prominent generic drug manufacturer, the company operates with an integrated business model that spans from high-tech R&D to brand management and distribution. Adhering to international quality standards and ISO 9001 certification, it focuses on technological innovation and sustainable growth to serve diverse healthcare needs across domestic and international markets.

Recent filings

Filing Released Lang Actions
公告董事會通過113年第一季合併財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1720 生達) reporting the board's approval of the consolidated financial report for the first quarter of the year 113 (Taiwan calendar, equivalent to 2024). It includes detailed financial figures for the period 113/01/01 to 113/03/31, such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity. The document is 907 characters long, which is relatively short but contains substantive financial data and analysis for a quarterly period. It is not merely an announcement of a report publication but the actual financial summary approved by the board. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-05-07 Chinese
113年04月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tables listing shareholdings of insiders, including directors, managers, and their related parties. It shows the number of shares held, changes in holdings, and classifications of shares for various insiders. This type of document is typical of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of financial statements, earnings data, or meeting materials. The document is not an announcement of a report but a detailed disclosure of insider shareholdings and transactions. Therefore, the appropriate classification is Director's Dealing (DIRS).
2024-05-07 Chinese
113年04月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, supervisors, and senior management, with specific numbers of shares held, pledged shares, and related party holdings. The content focuses on insider shareholdings and their changes, which is characteristic of a Director's Dealing or insider share transaction report. There is no indication of financial results, management discussion, or regulatory announcements unrelated to insider holdings. The document length is short (2688 characters) and does not mention any report publication or certification. Therefore, the document is best classified as a Director's Dealing report.
2024-05-07 Chinese
公告本公司民國113年第一季財務報告董事會召開日期
Regulatory Filings Classification · 95% confidence The document is a short announcement (539 characters) from a company (1720 生達) stating the date of the board meeting to be held on 113/05/07 to discuss the first quarter financial report of the year 113 (Taiwan calendar). It does not contain the financial report itself but only announces the upcoming board meeting and the expected agenda regarding the quarterly financial report. This fits the pattern of a Regulatory Filing (RNS) as it is a regulatory announcement about a meeting and report timing, not the report itself. The document is too short and does not contain actual financial data or detailed report content, so it cannot be classified as an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-04-29 Chinese
113年04月法人說明會簡報 — 172020240424E001.pdf
Annual Report Classification · 95% confidence The document is titled '2024 Investor Conference 4/25/2024' and contains detailed financial data including consolidated income statements, balance sheets, cash flows, and EPS figures for 2023 and prior years. It also includes future operation strategy and corporate social responsibility sections. The presence of detailed financial statements and operating results for the full year 2023 indicates this is a comprehensive financial report rather than a brief earnings release or a simple announcement. The length of the document (15,000 characters) and the inclusion of multiple financial tables and strategic outlook further support this. The document is not a transcript of a call, nor a proxy or voting announcement, nor a regulatory filing or certification. It is a detailed annual financial report covering company activity and full financial performance for the year 2023. Therefore, the appropriate classification is Annual Report (10-K).
2024-04-24 Chinese
113年04月法人說明會簡報 — 172020240424M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated April 25, 2024, by Standard Chem & Pharm Co., Ltd. It includes forward-looking statements, operational results for 2023, future strategies, corporate social responsibility, and detailed financial data such as consolidated income statements, balance sheets, and cash flow statements. The content is structured as a slide presentation with multiple pages and charts, typical of an investor or analyst presentation. It is not a formal annual report (10-K) or interim report (IR) because it is presented as a slide deck rather than a full regulatory filing. It is not an earnings release (ER) because it contains more comprehensive strategic and operational information beyond key financial highlights. It is not a regulatory filing or report publication announcement since it contains substantive financial and strategic content. The presence of forward-looking statements and detailed business strategy aligns with an Investor Presentation (IP). Therefore, the document is best classified as an Investor Presentation (IP).
2024-04-24 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.